Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1987 1
1997 2
1999 2
2000 3
2001 6
2002 7
2003 7
2004 7
2005 6
2006 7
2007 3
2008 4
2009 1
2010 3
2011 2
2012 4
2013 13
2014 14
2015 9
2016 9
2017 16
2018 12
2019 15
2020 14
2021 17
2022 14
2023 6
2024 4

Text availability

Article attribute

Article type

Publication date

Search Results

183 results

Results by year

Filters applied: . Clear all
Page 1
The Vascular Impairment of Cognition Classification Consensus Study.
Skrobot OA, O'Brien J, Black S, Chen C, DeCarli C, Erkinjuntti T, Ford GA, Kalaria RN, Pantoni L, Pasquier F, Roman GC, Wallin A, Sachdev P, Skoog I; VICCCS group; Ben-Shlomo Y, Passmore AP, Love S, Kehoe PG. Skrobot OA, et al. Alzheimers Dement. 2017 Jun;13(6):624-633. doi: 10.1016/j.jalz.2016.10.007. Epub 2016 Dec 10. Alzheimers Dement. 2017. PMID: 27960092 Free article.
Donanemab in Early Symptomatic Alzheimer Disease: The TRAILBLAZER-ALZ 2 Randomized Clinical Trial.
Sims JR, Zimmer JA, Evans CD, Lu M, Ardayfio P, Sparks J, Wessels AM, Shcherbinin S, Wang H, Monkul Nery ES, Collins EC, Solomon P, Salloway S, Apostolova LG, Hansson O, Ritchie C, Brooks DA, Mintun M, Skovronsky DM; TRAILBLAZER-ALZ 2 Investigators. Sims JR, et al. JAMA. 2023 Aug 8;330(6):512-527. doi: 10.1001/jama.2023.13239. JAMA. 2023. PMID: 37459141 Free PMC article.
Progress toward standardized diagnosis of vascular cognitive impairment: Guidelines from the Vascular Impairment of Cognition Classification Consensus Study.
Skrobot OA, Black SE, Chen C, DeCarli C, Erkinjuntti T, Ford GA, Kalaria RN, O'Brien J, Pantoni L, Pasquier F, Roman GC, Wallin A, Sachdev P, Skoog I; VICCCS group; Ben-Shlomo Y, Passmore AP, Love S, Kehoe PG. Skrobot OA, et al. Alzheimers Dement. 2018 Mar;14(3):280-292. doi: 10.1016/j.jalz.2017.09.007. Epub 2017 Oct 19. Alzheimers Dement. 2018. PMID: 29055812 Free article.
Safety and Efficacy of Semorinemab in Individuals With Prodromal to Mild Alzheimer Disease: A Randomized Clinical Trial.
Teng E, Manser PT, Pickthorn K, Brunstein F, Blendstrup M, Sanabria Bohorquez S, Wildsmith KR, Toth B, Dolton M, Ramakrishnan V, Bobbala A, Sikkes SAM, Ward M, Fuji RN, Kerchner GA; Tauriel Investigators. Teng E, et al. JAMA Neurol. 2022 Aug 1;79(8):758-767. doi: 10.1001/jamaneurol.2022.1375. JAMA Neurol. 2022. PMID: 35696185 Free PMC article. Clinical Trial.
Diagnostic criteria for vascular cognitive disorders: a VASCOG statement.
Sachdev P, Kalaria R, O'Brien J, Skoog I, Alladi S, Black SE, Blacker D, Blazer DG, Chen C, Chui H, Ganguli M, Jellinger K, Jeste DV, Pasquier F, Paulsen J, Prins N, Rockwood K, Roman G, Scheltens P; Internationlal Society for Vascular Behavioral and Cognitive Disorders. Sachdev P, et al. Among authors: prins n. Alzheimer Dis Assoc Disord. 2014 Jul-Sep;28(3):206-18. doi: 10.1097/WAD.0000000000000034. Alzheimer Dis Assoc Disord. 2014. PMID: 24632990 Free PMC article.
Amyloid imaging in prodromal Alzheimer's disease.
Ossenkoppele R, van Berckel BN, Prins ND. Ossenkoppele R, et al. Among authors: prins nd. Alzheimers Res Ther. 2011 Sep 19;3(5):26. doi: 10.1186/alzrt88. Alzheimers Res Ther. 2011. PMID: 21936965 Free PMC article.
Preclinical and randomized clinical evaluation of the p38α kinase inhibitor neflamapimod for basal forebrain cholinergic degeneration.
Jiang Y, Alam JJ, Gomperts SN, Maruff P, Lemstra AW, Germann UA, Stavrides PH, Darji S, Malampati S, Peddy J, Bleiwas C, Pawlik M, Pensalfini A, Yang DS, Subbanna S, Basavarajappa BS, Smiley JF, Gardner A, Blackburn K, Chu HM, Prins ND, Teunissen CE, Harrison JE, Scheltens P, Nixon RA. Jiang Y, et al. Among authors: prins nd. Nat Commun. 2022 Sep 21;13(1):5308. doi: 10.1038/s41467-022-32944-3. Nat Commun. 2022. PMID: 36130946 Free PMC article. Clinical Trial.
Diversity in Alzheimer's disease drug trials: The importance of eligibility criteria.
Franzen S, Smith JE, van den Berg E, Rivera Mindt M, van Bruchem-Visser RL, Abner EL, Schneider LS, Prins ND, Babulal GM, Papma JM. Franzen S, et al. Among authors: prins nd. Alzheimers Dement. 2022 Apr;18(4):810-823. doi: 10.1002/alz.12433. Epub 2021 Sep 30. Alzheimers Dement. 2022. PMID: 34590409 Free PMC article. Review.
ATN classification and clinical progression in subjective cognitive decline: The SCIENCe project.
Ebenau JL, Timmers T, Wesselman LMP, Verberk IMW, Verfaillie SCJ, Slot RER, van Harten AC, Teunissen CE, Barkhof F, van den Bosch KA, van Leeuwenstijn M, Tomassen J, Braber AD, Visser PJ, Prins ND, Sikkes SAM, Scheltens P, van Berckel BNM, van der Flier WM. Ebenau JL, et al. Among authors: prins nd. Neurology. 2020 Jul 7;95(1):e46-e58. doi: 10.1212/WNL.0000000000009724. Epub 2020 Jun 10. Neurology. 2020. PMID: 32522798 Free PMC article.
Can novel therapeutics halt the amyloid cascade?
Prins ND, Visser PJ, Scheltens P. Prins ND, et al. Alzheimers Res Ther. 2010 Apr 9;2(2):5. doi: 10.1186/alzrt28. Alzheimers Res Ther. 2010. PMID: 20388189 Free PMC article.
183 results